Ask AI

Precision in Practice: Implementing HER2 Testing and HER2-Directed Therapy in Gynecologic Cancers

These downloadable slides examine the evolving role of HER2 as a clinically actionable biomarker in gynecologic cancers, with emphasis on how HER2 testing, interpretation of test results, and treatment evidence should inform patient selection and management. Differences among HER2 protein expression, gene amplification, and activating mutations; practical issues in IHC and ISH testing; causes of discordant or heterogeneous results; and guideline-aligned testing approaches across endometrial, cervical, ovarian, and other gynecologic malignancies are also reviewed. The slides summarize clinical evidence for HER2-directed therapy, including trastuzumab-based strategies and antibody–drug conjugates such as trastuzumab deruxtecan, with data from studies including DESTINY-PanTumor02 and STATICE demonstrating activity in HER2-expressing endometrial, cervical, ovarian, and uterine carcinosarcoma populations.

HER2 Testing and Therapy in Gynecologic Cancers

Activity Information

Released: August 20, 2026